Who Generates More Revenue? Bristol-Myers Squibb Company or Merus N.V.

Bristol-Myers Squibb vs. Merus N.V.: A Revenue Comparison

__timestampBristol-Myers Squibb CompanyMerus N.V.
Wednesday, January 1, 201415879000000944841
Thursday, January 1, 2015165600000001437692
Friday, January 1, 2016194270000002859576
Sunday, January 1, 20172077600000014882309
Monday, January 1, 20182256100000035973461
Tuesday, January 1, 20192614500000031133000
Wednesday, January 1, 20204251800000029943000
Friday, January 1, 20214638500000049107000
Saturday, January 1, 20224615900000041586000
Sunday, January 1, 20234500600000043947000
Monday, January 1, 202448300000000
Loading chart...

Infusing magic into the data realm

Revenue Showdown: Bristol-Myers Squibb vs. Merus N.V.

In the competitive landscape of the pharmaceutical industry, revenue generation is a key indicator of a company's market position and growth potential. Over the past decade, Bristol-Myers Squibb Company has consistently outperformed Merus N.V. in terms of revenue. From 2014 to 2023, Bristol-Myers Squibb's revenue surged by approximately 184%, peaking in 2021 with a staggering $46 billion. In contrast, Merus N.V., a smaller player in the industry, saw its revenue grow from under $1 million in 2014 to nearly $44 million in 2023, marking an impressive growth rate of over 4,500%.

While Bristol-Myers Squibb's revenue dwarfs that of Merus N.V., the latter's rapid growth highlights its potential in the biotech sector. This comparison underscores the diverse strategies and market dynamics at play within the pharmaceutical industry, where both established giants and emerging innovators vie for market share.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025